Drug Profile
Losartan/hydrochlorothiazide
Alternative Names: Cozaar Plus; Cozaarex D; Hizaar; Hyzaar; Lorzaar Plus; Losartan potassium/hydrochlorothiazide; Losazid; MK 954H; MK-0954A; Neo Lotan Plus; PreminentLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Banyu; Merck Sharp & Dohme; Neopharmed Gentili; sigma-tau SpA
- Class Antihypertensives; Benzothiadiazines; Biphenyl compounds; Imidazoles; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; Diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypertension
Most Recent Events
- 26 Jan 2012 Generic equivalent available in Canada for Hypertension
- 12 Jan 2012 Merck completes enrolment in its phase III trial for Hypertension in Japan (NCT01307046)
- 27 Jul 2010 Generic equivalent available in USA for Hypertension